A single intradiscal injection of SI-6603 demonstrated significantly greater improvement in leg pain vs. sham at Week 13 in trials…
Parsippany, NJ – September 9, 2024 – Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikagaku), today announced they…
A single intradiscal injection of SI-6603 demonstrated significantly greater improvement in leg pain vs. sham at Week 13 with notable…
Parsippany, NJ – June 24, 2024 – Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikagaku), today announced the…
1 in 6 people worldwide experience infertility and up to 50% of the time there is a contributing male factor.1,2,3 Stigma,…
First real-world outcomes analysis evaluated efficacy of REBYOTA in patients with recurrent C. diff infection Ad-hoc analysis evaluated efficacy and…
SI-6603 is an investigational therapy intended to treat radicular leg pain associated with lumbar disc herniation Lumbar disc herniation can…
Final analysis shows ADSTILADRIN was well-tolerated with no new study drug-related adverse events — <4% of patients experienced Grade 3…
Biopharmaceutical contract manufacturer SK pharmteco commits to production, testing, and release of Ferring’s U.S. approved ADSTILADRIN® (nadofaragene firadenovec-vncg) The deal…
Expanded clinical trial program with ADSTILADRIN starts up in the United States Current clinical trial program of five multi-year studies…